Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP10 | Q14694 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20690298 | 0.88 | VCAM1 (0.59) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL20594866 | 0.87 | VCAM1 (0.59) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL13529954 | 0.87 | NOTUM (0.60) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL3855174 | 0.83 | CASP6 (0.64) | LMNAKMT2AMEN1 | |
| SCHEMBL12326836 | 0.83 | MAPT (0.51) | VCAM1ALDH1A1CHEK1LMNAKMT2A | |
| SCHEMBL5734347 | 0.82 | VCAM1 (0.68) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL30792131 | 0.82 | VCAM1 (0.52) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL8149078 | 0.82 | CHEK1 (0.55) | VCAM1HPGDALDH1A1NPSR1CHEK1 | |
| SCHEMBL30409276 | 0.82 | VCAM1 (0.53) | VCAM1HPGDALDH1A1NPSR1LMNA | |
| SCHEMBL11378677 | 0.81 | VCAM1 (0.62) | VCAM1HPGDALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655203-B2 | Nitration | ETH ZURICH (CH) | 2023-05-23 | — | — | US | disclosed |
| US-11655203-B2 | Nitration | ETH ZURICH (CH) | 2023-05-23 | — | — | US | disclosed |
| US-20220009875-A1 | NITRATION | ETH ZURICH (CH) | 2022-01-13 | — | — | US | disclosed |
| CN-113302186-A | Nitration | 瑞士苏黎世联邦理工学院 | 2021-08-24 | — | — | CN | disclosed |
| EP-3717464-B1 | NITRATION | ETH ZUERICH (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3717464-A1 | NITRATION | ETH Zurich (CH) | 2020-10-07 | — | — | EP | disclosed |
| US-20190290784-A1 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2019-09-26 | — | — | US | disclosed |
| US-10328161-B2 | Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-25 | — | — | US | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-6040339-A | TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL | SANKYO COMPANY, LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009875-A1 | NITRATION | NOS1, NOS2, NOS3 | VCAM1 3794/4885HPGD 464/4885ALDH1A1 2335/4885 |
| US-10328161-B2 | Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof | GFPT1, QPCT, GLB1 | VCAM1 3977/4885HPGD 1078/4885ALDH1A1 3234/4885 |
| US-20190290784-A1 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF | GFPT1, QPCT, GLB1 | VCAM1 3977/4885HPGD 1078/4885ALDH1A1 3234/4885 |
| US-11655203-B2 | Nitration | NOS1, NOS2, NOS3 | VCAM1 3794/4885HPGD 464/4885ALDH1A1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.